{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017044","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.713954+00:00","generated_at":"2026-06-01T22:45:36.310145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal","bullets":["Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.","Cash + short-term investments $230.3M at Mar 31, up $58.5M from Dec 31; includes $115.5M from DRI royalty deal.","Sold DRI expanded OMIDRIA royalty: DRI gets all US royalties through 2031; Omeros retains ex-US & post-2031 global; potential milestones up to $27.5M each.","OMS906 Phase 2 PNH data at EHA June 15; Phase 3 start late 2024. Narsoplimab BLA resubmission timeline uncertain pending FDA.","Repurchased 3.2M shares for $11.9M in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017044","json":"https://secwatch.observer/filing/0001437749-24-017044.json","markdown":"https://secwatch.observer/filing/0001437749-24-017044.md","text":"https://secwatch.observer/filing/0001437749-24-017044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924017044/0001437749-24-017044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924017044/omer20240415_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:45:36.310145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd9b7831f3ac4683f45228eb4e8ca4d9c6be0cfb","claim":"OMEROS CORP reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, EPS $0.63 per share.","evidence_excerpt":"Omeros Corporation Reports First Quarter 2024 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924017044/0001437749-24-017044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share"},{"label":"EPS","value":"$0.63 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}